Zx. Shen et al., USE OF ARSENIC TRIOXIDE (AS2O3) IN THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APE) .2. CLINICAL EFFICACY AND PHARMACOKINETICS IN RELAPSED PATIENTS, Blood, 89(9), 1997, pp. 3354-3360
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of
acute promyelocytic leukemia (APL) was evaluated among 15 APL patient
s at relapse after all-trans retinoic acid (ATRA) induced and chemothe
rapy maintained complete remission (CW). As2O3 was administered intrav
enously at the dose of 10 mg/d. Clinical CR was achieved in nine of 10
(90%) patients treated with As2O3 alone and in the remaining five pat
ients treated by the combination of As2O3 and low-dose chemotherapeuti
c drugs or ATRA. During the treatment with As2O3, there was no bone ma
rrow depression and only limited side effects were encountered. Pharma
cokinetic studies, which were performed in eight patients, showed that
after a peak level of 5.54 mu mol/L to 7.30 mu mol/L, plasma arsenic
was rapidly eliminated, and the continuous administration of As2O3 did
not alter its pharmacokinetic behaviors. In addition, increased amoun
ts of arsenic appeared in the urine, with a daily excretion accounting
for approximately 1% to 8% of the total daily dose administered. Arse
nic contents in hair and nail were increased, and the peak content of
arsenic could reach 2.5 to 2.7 mu g/g tissue at GR. On the other hand,
a decline of the arsenic content in hair and nail was observed after
withdrawal of the drug. We conclude that As2O3, treatment is an effect
ive and relatively safe drug in APL patients refractory to ATRA and co
nventional chemotherapy. (C) 1997 by The American Society of Hematolog
y.